Litcius/Paper detail

Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors

Bram Herpers, Berina Eppink, Mark I. James, Carme Cortina, Adrià Cañellas‐Socias, Sylvia F. Boj, Xavier Hernando‐Momblona, Dominik Głodzik, Rob C. Roovers, Marc van de Wetering, Carina Bartelink-Clements, Vanessa Zondag-van der Zande, Jara García Mateos, Kuan Yan, Lucia Salinaro, Abdul Basmeleh, Szabolcs Fátrai, David Maussang, Jeroen J. Lammerts van Bueren, Irene Chicote, Garazi Serna, Laia Cabellos, Lorena Ramírez, Paolo Nucíforo, Ramón Salazar, Cristina Santos, Alberto Villanueva, Camille Stephan‐Otto Attolini, Elena Sancho, Héctor G. Pálmer, Josep Tabernero, Michael R. Stratton, John de Kruif, Ton Logtenberg, Hans Clevers, Leo Price, Robert G.J. Vries, Eduard Batlle, Mark Throsby

2022Nature Cancer159 citationsDOIOpen Access PDF

Topics & Concepts

LGR5OrganoidCancer researchEpidermal growth factor receptorColorectal cancerCancer stem cellKRASStem cellCancerWnt signaling pathwayCetuximabMedicineReceptor tyrosine kinaseBiologyReceptorInternal medicineSignal transductionCell biologyCancer Cells and MetastasisCancer Research and Treatments3D Printing in Biomedical Research
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors | Litcius